ELI LILLY & Co (LLY) stock
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 19/3025% above fair value
$1415.55−16.12 (-1.13%)
Close on Nov 17, 2026Market cap $1.33TP/E 45.9Yield 0.44%
Eli Lilly operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Eli Lilly's operating cash flow for the twelve months ending Sep 30, 2026 was $30.65B, up 90.8% year over year. For fiscal 2025 it was $16.81B, up 90.7% from the year before. Over ten years it grew 19.0% a year on average. The highest annual figure on record is $16.81B in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.81B | +90.7% |
| FY2024 | Dec 31, 2024 | $8.82B | +108.0% |
| FY2023 | Dec 31, 2023 | $4.24B | -44.1% |
| FY2022 | Dec 31, 2022 | $7.59B | +3.0% |
| FY2021 | Dec 31, 2021 | $7.37B | +13.3% |
| FY2020 | Dec 31, 2020 | $6.50B | +34.4% |
| FY2019 | Dec 31, 2019 | $4.84B | -12.5% |
| FY2018 | Dec 31, 2018 | $5.52B | -1.6% |
| FY2017 | Dec 31, 2017 | $5.62B | +15.8% |
| FY2016 | Dec 31, 2016 | $4.85B | +63.6% |
| FY2015 | Dec 31, 2015 | $2.96B | -33.5% |
| FY2014 | Dec 31, 2014 | $4.46B | -22.3% |
| FY2013 | Dec 31, 2013 | $5.74B | +8.1% |
| FY2012 | Dec 31, 2012 | $5.30B | -26.7% |
| FY2011 | Dec 31, 2011 | $7.23B | +5.5% |
| FY2010 | Dec 31, 2010 | $6.86B | +58.2% |
| FY2009 | Dec 31, 2009 | $4.34B | -40.6% |
| FY2008 | Dec 31, 2008 | $7.30B | +41.5% |
| FY2007 | Dec 31, 2007 | $5.15B | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $11.40B | +29.0% |
| Q2 FY2026 | Jun 30, 2026 | $10.69B | +246.3% |
| Q1 FY2026 | Mar 31, 2026 | $5.33B | +220.1% |
| Q4 FY2025 | Dec 31, 2025 | $3.23B | +30.4% |
| Q3 FY2025 | Sep 30, 2025 | $8.84B | +138.0% |
| Q2 FY2025 | Jun 30, 2025 | $3.09B | +110.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.67B | +42.9% |
| Q4 FY2024 | Dec 31, 2024 | $2.47B | – |
| Q3 FY2024 | Sep 30, 2024 | $3.71B | +69.5% |
| Q2 FY2024 | Jun 30, 2024 | $1.47B | +132.0% |
| Q1 FY2024 | Mar 31, 2024 | $1.17B | -32.6% |
| Q4 FY2023 | Dec 31, 2023 | -$312.00M | -118.8% |
| Q3 FY2023 | Sep 30, 2023 | $2.19B | -1.2% |
| Q2 FY2023 | Jun 30, 2023 | $631.90M | -46.6% |
| Q1 FY2023 | Mar 31, 2023 | $1.73B | -31.4% |
| Q4 FY2022 | Dec 31, 2022 | $1.66B | -26.5% |
| Q3 FY2022 | Sep 30, 2022 | $2.22B | +35.9% |
| Q2 FY2022 | Jun 30, 2022 | $1.18B | -33.4% |
| Q1 FY2022 | Mar 31, 2022 | $2.52B | +48.6% |
| Q4 FY2021 | Dec 31, 2021 | $2.26B | +24.6% |
| Q3 FY2021 | Sep 30, 2021 | $1.63B | -9.7% |
| Q2 FY2021 | Jun 30, 2021 | $1.78B | -28.8% |
| Q1 FY2021 | Mar 31, 2021 | $1.70B | +343.9% |
| Q4 FY2020 | Dec 31, 2020 | $1.82B | -7.6% |
| Q3 FY2020 | Sep 30, 2020 | $1.81B | +19.6% |
| Q2 FY2020 | Jun 30, 2020 | $2.50B | +137.3% |
| Q1 FY2020 | Mar 31, 2020 | $382.40M | +22.8% |
| Q4 FY2019 | Dec 31, 2019 | $1.96B | +35.5% |
| Q3 FY2019 | Sep 30, 2019 | $1.51B | -28.8% |
| Q2 FY2019 | Jun 30, 2019 | $1.05B | -30.7% |
| Q1 FY2019 | Mar 31, 2019 | $311.30M | -28.7% |
| Q4 FY2018 | Dec 31, 2018 | $1.45B | -16.9% |
| Q3 FY2018 | Sep 30, 2018 | $2.12B | +12.8% |
| Q2 FY2018 | Jun 30, 2018 | $1.52B | -8.1% |
| Q1 FY2018 | Mar 31, 2018 | $436.50M | +28.4% |
| Q4 FY2017 | Dec 31, 2017 | $1.74B | -13.1% |
| Q3 FY2017 | Sep 30, 2017 | $1.88B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.65B | – |
| Q1 FY2017 | Mar 31, 2017 | $339.90M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.01B | – |
See a number that looks wrong?